BioMarin Pharmaceutical (NASDAQ:BMRN) Shares Gap Down After Analyst Downgrade

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)’s stock price gapped down prior to trading on Tuesday after Royal Bank Of Canada lowered their price target on the stock from $62.00 to $60.00. The stock had previously closed at $57.44, but opened at $53.06. Royal Bank Of Canada currently has a sector perform rating on the stock. BioMarin Pharmaceutical shares last traded at $55.1030, with a volume of 411,376 shares trading hands.

Several other research firms have also recently weighed in on BMRN. Canaccord Genuity Group boosted their price objective on BioMarin Pharmaceutical from $111.00 to $114.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. UBS Group started coverage on BioMarin Pharmaceutical in a research report on Thursday, October 15th. They issued a “buy” rating and a $88.00 price target on the stock. Oppenheimer reaffirmed an “outperform” rating and issued a $94.00 price target on shares of BioMarin Pharmaceutical in a research report on Tuesday. William Blair upgraded BioMarin Pharmaceutical to a “hold” rating in a report on Wednesday, September 23rd. Finally, Jefferies Financial Group increased their price objective on BioMarin Pharmaceutical from $104.00 to $105.00 and gave the company a “buy” rating in a research report on Monday, August 31st. Three research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $88.09.

Key Headlines Impacting BioMarin Pharmaceutical

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: BioMarin reported third-quarter revenue of $1.025 billion, up 32% year over year and broadly in line with estimates. Growth was led by a 44% increase in metabolic-condition revenue and a 12% increase in skeletal-condition revenue. Adjusted EPS of $0.23 substantially exceeded the consensus estimate for a loss of approximately $0.08. BioMarin Reports Third Quarter 2026 Financial and Operating Results
• Positive Sentiment: The company expanded its pipeline with a new investigational Fabry-disease asset and reported a May 30, 2027, FDA action date for VOXZOGO in hypochondroplasia. These developments support BioMarin’s longer-term growth prospects. BioMarin Reports Third Quarter 2026 Financial and Operating Results
• Positive Sentiment: Citi reiterated a Buy rating, arguing that the timing-related setback does not undermine BioMarin’s long-term potential and citing approximately 32% upside. Other commentary described the stock as potentially undervalued following the Fabry deal and mixed guidance. BioMarin’s Timing-Related Setback Masks Long-Term Growth Potential
• Negative Sentiment: BioMarin lowered fiscal 2026 EPS guidance to $2.80–$3.10, below the $3.32 analyst consensus, and set revenue guidance at $3.8–$3.9 billion versus a $3.9 billion consensus. The lower outlook may outweigh the quarterly earnings beat in the near term. BMRN Q3 Deep Dive
• Neutral Sentiment: Management characterized the outlook issue as primarily related to order timing, while acquired IPR&D charges also affected earnings expectations. Investors will likely focus on whether demand timing normalizes and whether the expanded pipeline generates future growth.

Institutional Trading of BioMarin Pharmaceutical

Several institutional investors have recently modified their holdings of BMRN. Kestra Advisory Services LLC raised its position in BioMarin Pharmaceutical by 23.4% in the third quarter. Kestra Advisory Services LLC now owns 4,520 shares of the biotechnology company’s stock worth $271,000 after purchasing an additional 857 shares in the last quarter. Bfsg LLC bought a new position in BioMarin Pharmaceutical during the third quarter worth about $1,052,000. Oregon Public Employees Retirement Fund boosted its holdings in BioMarin Pharmaceutical by 0.5% during the third quarter. Oregon Public Employees Retirement Fund now owns 40,117 shares of the biotechnology company’s stock valued at $2,407,000 after purchasing an additional 200 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich acquired a new stake in BioMarin Pharmaceutical during the third quarter valued at approximately $186,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in BioMarin Pharmaceutical during the third quarter valued at approximately $705,000. Institutional investors and hedge funds own 98.71% of the company’s stock.

BioMarin Pharmaceutical Stock Performance

The company has a market capitalization of $10.61 billion, a P/E ratio of 148.14, a price-to-earnings-growth ratio of 0.61 and a beta of 0.22. The firm has a 50 day moving average price of $60.43 and a two-hundred day moving average price of $58.46. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.32 and a current ratio of 2.39.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its earnings results on Monday, November 2nd. The biotechnology company reported $0.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.31. The business had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.02 billion. BioMarin Pharmaceutical had a return on equity of 5.32% and a net margin of 2.14%. BioMarin Pharmaceutical’s quarterly revenue was up 32.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.12 EPS. On average, research analysts expect that BioMarin Pharmaceutical Inc. will post 2.59 earnings per share for the current fiscal year.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening rare diseases. The company’s research and development efforts center on genetic and metabolic disorders, where patient populations are often small and treatment options are limited.

BioMarin’s marketed products include Voxzogo (vosoritide) for children with achondroplasia and open growth plates, Palynziq (pegvaliase) and Kuvan (sapropterin dihydrochloride) for phenylketonuria, Brineura (cerliponase alfa) for late-infantile neuronal ceroid lipofuscinosis type 2, Vimizim (elosulfase alfa) for Morquio A syndrome, and Naglazyme (galsulfase) for mucopolysaccharidosis VI.